The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.

The troubled conglomerate is accelerating its moves to streamline its business, with the creation of a more customer- and US-focused pharma division.

Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.

The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.